Investor · 1 deal
Every published round Agati Capital took part in, and every parcel of existing shares it bought off another holder. Deals we hold but haven't published yet are not counted.
| Company | Stage | Announced | Amount | Role | Alongside | Sources |
|---|---|---|---|---|---|---|
| Aravax | Series B | 28 Jan 2024 | $66m | Participant | Startup News (WA), Forbes Australia, @AuManufacturing (28 Jan 2024), Business News Australia, Brandon BioCatalyst, Brandon Capital, @AuManufacturing (23 Jan 2024), Breakthrough Victoria, Tenmile portfolio |
Companies Agati Capital has backed in a published round, and companies whose existing shares it bought off another holder.
| Company | What it does | First invested | Rounds | Led |
|---|---|---|---|---|
| Aravax | Biotech company running a Phase 2 peanut allergy trial | 28 Jan 2024, Series B | 1 | 0 |
Fund closes reported for Agati Capital, as distinct from the investments it has made.
Companies Agati Capital has backed that another company then bought. An exit for the holding, not a deal Agati Capital did.
Stories naming Agati Capital. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Aravax has finished enrolling 95 young patients in its Phase 2 peanut-allergy immunotherapy trial across US and Australian sites, with results expected in the first half of 2026.
Breakthrough Victoria announces a $12 million investment in Aravax, part of a $66 million Series B, advancing the biotech's peanut allergy immunotherapy into phase two trials in Australia and the United States.
Also Brandon Capital portfolio·Brandon BioCatalyst portfolio·@AuManufacturing·Business News Australia·@AuManufacturing·Forbes Australia·Startup News (WA)